Thank you to our speakers, sponsors, and delegates who joined us in 2024 for the summit!Β
If you are interested in the 2025 event, please get in touch at info@hansonwade.com.Β
What Happened at the 3rd In Vivo Cell Engineering & Gene Editing Summit?
This was the ONLY event focused on both cellular and genetic frontiers
With promising pre-clinical results continuing to emerge, the shift from the βdreamβ of in vivo cell engineering and gene editing had rapidly become a reality, with numerous companies pushing towards the clinic.
The 3rd In Vivo Cell Engineering & Gene Editing Summit was an exclusive platform offering the latest advances in preclinical development, IND-enabling studies, first clinical data readouts, and more, while also providing clarity on the full in vivo landscape.
Attendees united with industry giants like Capstan Therapeutics, Editas Medicine, NanoCell Therapeutics, Carisma Therapeutics, Mustang Bio, iECURE, and many others, gaining exclusive access to groundbreaking discoveries and networking opportunities that set them up to propel their pipelines to new heights!
Key 2025 Highlights
Exploring data-driven case studies to outline decision making when selecting viral versus non-viral vectorsΒ
Clarifying regulatory expectations for this novel therapeutic approachΒ to map out the future of your pipeline
Benchmarking appropriate preclinical models to support translationΒ to gain valuable data needed by regulatory bodies
Outlining the considerations when scaling up towards the clinic to equip you with the tools to tackle bottlenecks
Emphasizing target specificity and the mitigation of off-site toxicities to ensure safety is front of mind in development
Download the 2024 Agenda for More Information on:
-
-
-
- 17+ In Vivo Expert Speakers
- 2 Interactive Deep-Dive Workshops
- 8+ Hours of Industry Networking
- & Much More!
-
-
World-Class Speaker Faculty Included:
Our 2024 Partner
